Last reviewed · How we verify

KVA12123 Plus Pembrolizumab - Dose Expansion

Kineta Inc. · Phase 1 active Small molecule

KVA12123 Plus Pembrolizumab - Dose Expansion is a Small molecule drug developed by Kineta Inc.. It is currently in Phase 1 development. Also known as: Keytruda.

At a glance

Generic nameKVA12123 Plus Pembrolizumab - Dose Expansion
Also known asKeytruda
SponsorKineta Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about KVA12123 Plus Pembrolizumab - Dose Expansion

What is KVA12123 Plus Pembrolizumab - Dose Expansion?

KVA12123 Plus Pembrolizumab - Dose Expansion is a Small molecule drug developed by Kineta Inc..

Who makes KVA12123 Plus Pembrolizumab - Dose Expansion?

KVA12123 Plus Pembrolizumab - Dose Expansion is developed by Kineta Inc. (see full Kineta Inc. pipeline at /company/kineta-inc).

Is KVA12123 Plus Pembrolizumab - Dose Expansion also known as anything else?

KVA12123 Plus Pembrolizumab - Dose Expansion is also known as Keytruda.

What development phase is KVA12123 Plus Pembrolizumab - Dose Expansion in?

KVA12123 Plus Pembrolizumab - Dose Expansion is in Phase 1.

Related